<DOC>
	<DOCNO>NCT02018549</DOCNO>
	<brief_summary>Phase IIa , single center , open-label , single-arm study , evaluate inspiration profile NEXThaler device adult COPD patient vary degree airflow limitation</brief_summary>
	<brief_title>An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler DPI</brief_title>
	<detailed_description>As exploratory study , total 70 80 complete patient , ensure follow distribution term COPD Stage per GOLD 2013 ( update ) spirometric classification disease severity , deem sufficient assess inhalation profile NEXThaler® : - 10 20 COPD GOLD Stage I patient - 20 patient COPD GOLD Stage II IV . Assuming screen failure/drop-out rate 10 % , maximum 89 patient screen order reach require number complete patient . All analysis perform separately first second inhalation . Results stratify disease severity overall present .</detailed_description>
	<criteria>1 . Written inform consent obtain patient and/or legal representative 2 . Inpatients outpatient sex , age ≥ 40 year 3 . Documented clinical diagnosis ( within past 6 month ) COPD vary degree airflow limitation base Spirometric classification disease severity accord GOLD 2013 ( update ) guideline smoke history least 10 pack year ( packyears = number cigarette pack per day time number year ) . Current smoker exsmokers eligible 4 . A cooperative attitude ability use DPIs train proper use NEXThaler® confirm activation training device BAM 1 . Pregnant woman confirm positive pregnancy test nursing ( lactate ) woman ( applicable ) 2 . Diagnosis asthma 3 . Diagnosis restrictive lung disease 4 . Allergy component placebo treatment 5 . Inability comply study procedure treatment 6 . Significant unstable medical history and/or treatment cardiac , renal , neurological , hepatic , endocrine disease , previously document laboratory abnormality indicative significant underlying condition , may interfere patient 's safety , compliance , study evaluation , accord investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>COPD</keyword>
	<keyword>placebo</keyword>
	<keyword>inhalatory profile</keyword>
</DOC>